Susquehanna Fundamental Investments LLC purchased a new position in Inogen, Inc. (NASDAQ:INGN – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,032 shares of the medical technology company’s stock, valued at approximately $81,000.
Other hedge funds also recently modified their holdings of the company. Assenagon Asset Management S.A. increased its stake in Inogen by 26.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 285,176 shares of the medical technology company’s stock worth $1,566,000 after purchasing an additional 59,446 shares in the last quarter. Federated Hermes Inc. raised its stake in shares of Inogen by 347.2% in the 4th quarter. Federated Hermes Inc. now owns 265,485 shares of the medical technology company’s stock valued at $1,458,000 after purchasing an additional 206,125 shares during the period. Stokes Family Office LLC acquired a new stake in Inogen in the 1st quarter valued at approximately $351,000. Strs Ohio lifted its stake in Inogen by 9.0% in the 4th quarter. Strs Ohio now owns 41,300 shares of the medical technology company’s stock valued at $226,000 after acquiring an additional 3,400 shares in the last quarter. Finally, Jump Financial LLC grew its stake in shares of Inogen by 153.0% during the 4th quarter. Jump Financial LLC now owns 39,728 shares of the medical technology company’s stock worth $218,000 after acquiring an additional 24,028 shares in the last quarter. Institutional investors and hedge funds own 89.94% of the company’s stock.
Analysts Set New Price Targets
Several research analysts recently commented on INGN shares. Stifel Nicolaus increased their price target on Inogen from $6.00 to $7.00 and gave the company a “hold” rating in a research report on Wednesday, May 8th. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a report on Wednesday, May 8th. Finally, StockNews.com raised Inogen from a “sell” rating to a “hold” rating in a report on Monday, June 24th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $7.00.
View Our Latest Stock Report on INGN
Inogen Stock Performance
Shares of NASDAQ:INGN opened at $9.62 on Thursday. Inogen, Inc. has a 12-month low of $4.13 and a 12-month high of $10.64. The business has a 50 day moving average of $8.39 and a 200-day moving average of $7.54.
Inogen (NASDAQ:INGN – Get Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The medical technology company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.14. Inogen had a negative return on equity of 42.87% and a negative net margin of 30.07%. The firm had revenue of $78.03 million for the quarter, compared to analyst estimates of $73.67 million. During the same period in the prior year, the firm posted ($0.63) EPS. The company’s revenue for the quarter was up 8.1% on a year-over-year basis. As a group, analysts expect that Inogen, Inc. will post -2.2 EPS for the current year.
Insiders Place Their Bets
In related news, EVP Jason Somer sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $8.56, for a total value of $85,600.00. Following the completion of the sale, the executive vice president now directly owns 4,452 shares in the company, valued at $38,109.12. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.99% of the company’s stock.
Inogen Profile
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
See Also
Receive News & Ratings for Inogen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inogen and related companies with MarketBeat.com’s FREE daily email newsletter.
